UPDATE: ALR Technologies Announces Sales Guidance for Q4 2022, Q1 2023, and Completion of the GluCurve Pet CGM Manufacturing Agreement – Yahoo Finance
SINGAPORE, Dec. 29, 2022 (GLOBE NEWSWIRE) — ALR Technologies SG Ltd. (“ALRT”) (OTCQB:ALRTF), the diabetes management company, today announced the completion of a long-term manufacturing and supply agreement with Infinovo Medical Co. Ltd (“Infinovo”) for the Continuous Glucose Monitor (CGM) hardware used in the GluCurve Pet CGM. The agreement gives ALRT the exclusive global rights to distribute the CGM hardware in the animal health market.
Additionally, the Company announces it anticipates December and fourth quarter of 2022 sales to be in the range of $145,000 and $155,000. The Company expects Q1 2023 sales to be in the range of $450,000 to $600,000 with the possibility of an adjustment upwards subject to increased production capacity.
“December reflects a turning point for ALRT as we look to close out the fiscal year with our first quarter of meaningful sales, along with an attractive gross profit,” said Sidney Chan, Chairman and CEO of ALRT. “We will be exhibiting the GluCurve Pet CGM at CES January 5th-8th and VMX (Veterinary Meeting and Expo) January 14th-18th which should bolster awareness around the Company and GluCurve. The number of available units will increase quarter over quarter throughout 2023 resulting in a significant rise in sales as it will enable our distribution partner, Covetrus, to launch GluCurve throughout the US, EU, and other key markets.”
About Infinovo Medical Co. Ltd:
Founded in 2016, Infinovo is an innovative medical technology company, focusing on developing an accurate and affordable CGM for patients which will be available for both Type 1 and Type 2 Diabetics. https://infinovo.com
About ALR Technologies SG Ltd.
ALRT is a data management company that developed the ALRT Diabetes Solution, a comprehensive approach to diabetes care that includes an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters and continuous glucose monitoring devices, and a patent pending Predictive A1C algorithm to track treatment success between lab reports and an FDA-cleared Insulin Dosing Adjustment program. The overall goal is to optimize diabetes drug therapies to drive improved patient outcomes.
In addition, the animal health division of ALRT has developed the GluCurve Pet CGM; a solution to assist veterinarians better determine the efficacy of insulin treatments and to help to identify the appropriate dose and frequency of administration for companion animals, thereby delivering the same optimization of diabetic drug therapies to pets as to humans.
More information about ALRT can be found at www.alrt.com and https://sg.alrt.com.
Investor Contact
Investor Relations: ir@alrt.com
Animal Health Inquiries: animalhealth@alrt.com
Media: Media@alrt.com
US: +1 804 554 3500
Singapore: +65 3129 2924
ALR Technologies SG Ltd. Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding future sales and revenues, expected levels of product inventory and demand, strategy for customer retention, growth, product distribution, market penetration and expansion, financial results and reserves, and strategy for risk management. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: failure to generate anticipated company and product awareness, inability to maintain production capacity sufficient to meet customer demand for product, increased manufacturing costs, decreases in product market price, economic, regulatory, practical or other impediments to anticipated market expansion, and insufficient product demand. More information on these risks and other potential factors that could affect our business, reputation, results of operations, financial condition, and stock price is included in our filings with the SEC and subsequent filings. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Related Quotes
Here’s what you need to know about trading hours ahead of the holiday weekend. The New York Stock Exchange, the Nasdaq Stock Market, and over-the-counter markets will be open standard trading hours on Friday. The Tokyo Stock Exchange, the Shanghai Stock Exchange, the Hong Kong Stock Exchange, the Frankfurt Stock Exchange, and the Paris Stock Exchange will be open their normal hours on Friday.
Business magnate Warren Buffett is widely regarded as one of the greatest investors of the modern-day world. His seemingly unmatched and consistent value-investing strategies have earned him the title of Oracle of Omaha. Many of his investing strategies are known, but there is one that is often overlooked yet incredibly important. It’s a lot more prevalent in the startup investing world — one customer can mean all the difference for a startup but not necessarily for public companies. What happen
And what it means for your ability to build wealth.
There’s been a lot of talk about the downward economic pressures that have pummeled the markets in 2022 – maybe too much such talk. Yes, the S&P 500 is down almost 21%, and the NASDAQ is down 35%, but investors can still find sound opportunities. J.P. Morgan analyst Ryan Brinkman has been sorting through the automotive industry stocks, and he’s found several that are worth a closer look. So let’s do just that. We know that the auto industry has its own particular headwinds, including the ongoing
Diving into why investors with long-term horizons might seriously consider buying proven large-cap stocks poised to grow within essential industries heading into 2023 amid all of the uncertainty, recession fears, and selling.
Though the majority of publicly-traded real estate investment trusts (REITs) have been recovering over the past two months, the Federal Reserve’s hawkish stance combined with the macroeconomic uncertainties raise questions regarding their latest upswing. Following the slightly hotter-than-expected inflation data released earlier this month, the Federal Reserve will likely keep up its aggressive rate hikes in 2023, which might wipe out recent gains. This comes as Fed Chair Jerome Powell stated in
In this article, we take a look at 15 companies that are buying back stock. If you want to see more companies that are buying back stock, go directly to 5 Companies That Are Buying Back Their Stock. Stock buybacks and dividends are the two main ways companies return excess capital back to shareholders. Unlike […]
MicroStrategy, the company of Michael Saylor, one of the most fervent evangelists of Bitcoin, has sold the king of cryptocurrencies. The firm said it bought approximately 2,395 bitcoins for approximately $42.8 million in cash, at an average price of approximately $17,871 per bitcoin, inclusive of fees and expenses, between November 1 and December 21. The transaction was made at an average price of approximately $17,871 per bitcoin, inclusive of fees and expenses.
Portfolio concentration is a big reason the Oracle of Omaha has outperformed for more than a half-century.
"It does seem like we're headed into a recession here in 2023," Musk said on the "All-In Podcast" last week.
The penultimate trading day of 2022 brought a sigh of relief for investors in shares of Enovix (NASDAQ: ENVX), QuantumScape (NYSE: QS), and ChargePoint Holdings (NYSE: CHPT). As of 11:45 a.m. ET Thursday, while QuantumScape and ChargePoint stocks were trading 6.3% and 7.2% higher respectively, Enovix stock was up a solid 13.7%. This morning, the U.S. Department of Labor reported only a marginal increase in the filings for unemployment insurance for the week ending Dec. 24.
Yahoo Finance Live look to Tesla's recent stock actions following a newly announced tax credit for EV owners in 2023.
If you own a home or have been interested in buying one, you are aware of the sizeable U.S. residential real estate downturn. Sales numbers are dropping to their lowest rates since 2020, but interest rates continue to rise to around 6.5%. This scenario doesn’t mean investors should look to another option viewed as less volatile. Take real estate investment trusts (REITs), for example. REITs are not just a platform for investing in residential real estate, offering properties such as retail space
Stock markets would like to just get there without any more meaningful losses, says Navellier and Associate’s chairman and founder Louis Navellier, who adds that “anyone who made bets for a big rally this week is probably folding their tent.” The stock closed at a fresh 52-week low today [Wednesday] as it sliced through key support around $130.
Wednesday, the FDA approved TG Therapeutics Inc's (NASDAQ: TGTX) Briumvi (ublituximab-xiiy) for relapsing forms of multiple sclerosis (RMS). Briumvi is the first and only anti-CD20 monoclonal antibody approved for RMS that can be administered in a one-hour infusion following the starting dose. TG expects to launch Briumvi in the U.S. in 1Q23 commercially. HC Wainwright reiterates a Buy rating for the stock with a price target of $24, up from $19. The analyst writes that a faster infusion time co
These high-octane income stocks, with yields ranging from 4.5% to 6%, have been popular buys among select billionaire investors.
After spending most of 2022 on life support, shares of Chinese private education companies New Oriental Education & Technology (NYSE: EDU), TAL Education (NYSE: TAL), and Gaotu Techedu (NYSE: GOTU) finally caught a second wind in December, when the Chinese government repealed its zero-COVID policy and began to reopen its economy. With just 60 hours or so to go before the calendar flips to 2023, however, China is pulling the rug out from under investors again — and announcing new regulations on education companies.
A Tesla bull tries to be a hero on the plunging stock price.
Enphase Energy (ENPH) closed the most recent trading day at $265.49, moving -0.71% from the previous trading session.
Money can't buy you happiness, but what about working with a financial advisor?